Quoin Registers 9.37M ADSs for Resale — 144% Dilution Overhang Now Tradable
QNRX sits 98% above its 52-week low of $3.25.
Summary
Quoin's resale registration for 9.37M ADSs from its August private placement is now effective. Full warrant exercise would increase shares outstanding by 144.2% and could bring up to $19.1M in proceeds.
Key Events · Financing and Capital Events · QNRX
-
Resale Registration Effective
Registration statement covering 9,371,895 ADSs from the August 31 private placement is now effective, making those shares tradable by selling shareholders.
-
144.2% Dilution Overhang
If all pre-funded and ordinary warrants are exercised, ADSs outstanding would rise from 4,804,161 to 11,730,256 — a 144.2% increase.
-
Warrant Terms Disclosed
Ordinary warrants carry a $6.10 per ADS exercise price, exercisable for five years or until 30 days after the Netherton Syndrome primary endpoint is met.
-
Up to $19.1M Potential Proceeds
Full cash exercise of ordinary warrants would bring Quoin approximately $19.1 million, less placement agent fees, for general corporate purposes.
Analysis · QNRX · Life Sciences
The registration statement covering 9.37 million ADSs from Quoin's August private placement is now effective, making those shares tradable. The filing quantifies the dilution: if all pre-funded and ordinary warrants are exercised, the share count would rise 144.2% from 4.8 million to 11.7 million ADSs. The ordinary warrants carry a $6.10 exercise price, and full cash exercise would bring Quoin up to $19.1 million in additional proceeds. Against a backdrop of going-concern doubt and a $12.8 million market cap, this overhang is substantial — but the capital structure is now fully transparent, and the $6.10 strike sits just below the current $6.43 price, giving warrant holders an incentive to exercise and fund the company.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1531 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNRX was trading at $6.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $3.25 to $41.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.